Scioderm, Inc., an Amicus Therapeutics Company
Company

Scioderm, Inc., an Amicus Therapeutics Company

Biotechnology United States 2 employees FOLD
Employees
2

Scioderm, Inc., an Amicus Therapeutics Company Overview

Headquarters
United States
Phone Number
Available in AeroLeads
Website
sderm.com
Industry
Biotechnology
Employees
2
Founded
2012
Stock Symbol
FOLD
Funding
20.0M
Company Email
Available in AeroLeads

About Scioderm, Inc., an Amicus Therapeutics Company

Scioderm, Inc. was acquired by Amicus Therapeutics, Inc. in September of 2015. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare genetic diseases. Amicus, together with Scioderm, was developing an investigational topical treatment (SD-101) for people with Epidermolysis Bullosa (EB), which is a rare genetic connective tissue disorder. In September of 2017, results of a Phase 3 clinical study to assess the efficacy and safety of SD-101, showed that it did not show a statistically significant difference from placebo. Subsequently, Amicus discontinued the program, but shared the clinical data and additional information related to the EB program with key stakeholders including other companies with investigational treatments for EB as well as the broader EB community.

Scioderm, Inc., an Amicus Therapeutics Company Contact Details

People in AeroLeads
1

Scioderm, Inc., an Amicus Therapeutics Company Org Chart

Sample employees and titles
Name Title Contact
Muhammad Khalid Hussain Business Unit Head, Scioderm Pharma.
View

Compare Similar Companies to Scioderm, Inc., an Amicus Therapeutics Company